AUPH
Price
$17.33
Change
+$0.43 (+2.54%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
2.25B
12 days until earnings call
Intraday BUY SELL Signals
GOSS
Price
$9.43
Change
-$0.36 (-3.68%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
59.88M
13 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AUPH vs GOSS

AUPH vs GOSS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AUPH vs. GOSS commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUPH is a Buy and GOSS is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for AUPH with price predictions
Oct 21, 2026

AUPH in upward trend: price rose above 50-day moving average on October 08, 2026

AUPH moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend. In 44 of 48 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AUPH as a result. In 89 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.

The Moving Average Convergence Divergence (MACD) for AUPH just turned positive on October 12, 2026. Looking at past instances where AUPH's MACD turned positive, the stock continued to rise in 42 of 49 cases over the following month. The odds of a continued upward trend are 86%.

The 10-day moving average for AUPH crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.

Following a +2.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where AUPH advanced for three days, in 216 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 54 of 64 cases where AUPH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.

AUPH broke above its upper Bollinger Band on September 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 18 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. AUPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.657) is normal, around the industry mean (2.988). P/E Ratio (7.161) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (7.429) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for GOSS with price predictions
Oct 21, 2026

GOSS's Indicator enters downward trend

The Aroon Indicator for GOSS entered a downward trend on October 21, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 277 similar instances where the Aroon Indicator formed such a pattern. In 250 of the 277 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GOSS as a result. In 70 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The 10-day moving average for GOSS crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GOSS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 64 cases where GOSS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.

The Moving Average Convergence Divergence (MACD) for GOSS just turned positive on October 12, 2026. Looking at past instances where GOSS's MACD turned positive, the stock continued to rise in 35 of 38 cases over the following month. The odds of a continued upward trend are 90%.

The 50-day moving average for GOSS moved above the 200-day moving average on September 18, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +16.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where GOSS advanced for three days, in 214 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

GOSS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.637) is normal, around the industry mean (2.988). P/E Ratio (-0.231) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.666) is also within normal values, averaging (438.009).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. GOSS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GOSS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
AUPH vs GOSS: Fundamental Ratings
AUPH
GOSS
OUTLOOK RATING
1..100
1576
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
34
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
18100
PRICE GROWTH RATING
1..100
4386
P/E GROWTH RATING
1..100
9526
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GOSS's Valuation (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for AUPH (80) in the Biotechnology industry. This means that GOSS’s stock grew somewhat faster than AUPH’s over the last 12 months.

GOSS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as AUPH (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to AUPH’s over the last 12 months.

AUPH's SMR Rating (18) in the Biotechnology industry is significantly better than the same rating for GOSS (100) in the Pharmaceuticals Major industry. This means that AUPH’s stock grew significantly faster than GOSS’s over the last 12 months.

AUPH's Price Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for GOSS (86) in the Pharmaceuticals Major industry. This means that AUPH’s stock grew somewhat faster than GOSS’s over the last 12 months.

GOSS's P/E Growth Rating (26) in the Pharmaceuticals Major industry is significantly better than the same rating for AUPH (95) in the Biotechnology industry. This means that GOSS’s stock grew significantly faster than AUPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AUPHGOSS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
75%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
68%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (AUPH: $16.90 vs. GOSS: $9.79)
Brand notoriety: AUPH and GOSS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUPH: 94% vs. GOSS: 37%
Market capitalization -- AUPH: $2.31B vs. GOSS: $57.86M
AUPH [@Biotechnology] is valued at $2.31B. GOSS’s [@Biotechnology] market capitalization is $57.86M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUPH’s FA Score shows that 1 FA rating(s) are green while GOSS’s FA Score has 1 green FA rating(s).

  • AUPH’s FA Score: 1 green, 4 red.
  • GOSS’s FA Score: 1 green, 4 red.
According to our system of comparison, both AUPH and GOSS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUPH’s TA Score shows that 5 TA indicator(s) are bullish while GOSS’s TA Score has 5 bullish TA indicator(s).

  • AUPH’s TA Score: 5 bullish, 3 bearish.
  • GOSS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, AUPH is a better buy in the short-term than GOSS.

Price Growth

AUPH (@Biotechnology) experienced а +1.75% price change this week, while GOSS (@Biotechnology) price change was +9.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

AUPH is expected to report earnings on Nov 03, 2026.

GOSS is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
AUPH
Daily Signal:
Gain/Loss:
GOSS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

GOSS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with LITS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then LITS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GOSS
1D Price
Change %
GOSS100%
+2.19%
LITS - GOSS
46%
Loosely correlated
+4.20%
APVO - GOSS
41%
Loosely correlated
-0.93%
IDYA - GOSS
38%
Loosely correlated
+0.31%
XNCR - GOSS
38%
Loosely correlated
+0.88%
SYRE - GOSS
38%
Loosely correlated
+1.70%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EOS20.910.09
+0.43%
Eaton Vance Enhance Equity Income Fund II
AUMI90.910.33
+0.36%
Themes Gold Miners ETF (AUMI)
KBDU8.74N/A
N/A
KraneShares 2x Long BIDU Daily ETF (KBDU)
HTAX23.13-0.10
-0.42%
Macquarie National High-Yield Municipal Bond ETF
DFEN45.60-0.34
-0.74%
Direxion Daily Aerospace & Defense Bull 3X ETF (DFEN)